Incidence of SARS-CoV-2 (COVID-19) -associated pulmonary aspergillosis (CAPA) before and after dexamethasone therapy - a retrospective analysis

Incidence of SARS-CoV-2 (COVID-19) -associated pulmonary aspergillosis (CAPA) before and after dexamethasone therapy - a retrospective analysis - COVID DEXA

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00026071

Enrollment

200

Registered

2021-08-23

Start date

2021-05-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B44.0

Interventions

Group 1: Retrospective data analysis of all patients who had to be treated in the anesthesiological intensive care unit of essen university hospital between March 2020 and February 2021 due to COVID-1

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: COVID-19 Pneumonia Asp-Ag positive or culture pos or PCR pos

Exclusion criteria

Exclusion criteria: not fullfilled inclusion criteria

Design outcomes

Primary

Measure	Time frame
Occurence of CAPA	—

Secondary

Measure	Time frame
severity of illness	—

Countries

Germany

Contacts

Public ContactSimon Dubler

Universitätsklinikum Essen, Klinik für Anästhesie und Intensivmedizin

simon.dubler@uk-essen.de02017231401

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026